Catalog No.
Product Name
Application
Product Information
Citations
-
Parasite Inhibitor
(Rac)-ACT-451840 is a parasite inhibitor with significant antimalarial properties. It demonstrates effective antimalarial activity against P. berghei-infected mice, achieving an ED90 of 13 mg/kg and showing inhibitory effects at higher doses. In humanized immunodeficient mouse models infected with P. falciparum, the compound has an ED90 of 3.7 mg/kg. (Rac)-ACT-451840 is structurally similar to artemisinin and offers a rapid onset of action, although it necessitates repeated high dosing for optimal efficacy. -
Parasite
Aurachin B is a quinoline derivative that exerts its effects through inhibition of parasitic growth. This alkaloid displays significant antimalarial activity by interfering with the metabolism of Plasmodium species. It serves as a valuable tool for investigating therapeutic strategies against malaria and other parasitic infections. -
Parasite
Indoxacarb is an oxathiazole insecticide that targets a variety of insect pests by disrupting neuronal sodium channel activity, leading to paralysis and death. It is utilized in forest pest management, demonstrating significant toxicity toward the predatory stink bug Podisus distinctus, with a lethal concentration (LC50) of 2.62 g L-1. Exposure to Indoxacarb markedly decreases the survival rate of P. distinctus to 40.7% and diminishes its respiration rate from 18.45 to 14.41 μL CO2 h-1, along with reducing food intake. Furthermore, treated individuals exhibit hyperexcitation, indicating profound impacts on their physiological responses. -
Parasite
Acequinocyl is a naphthoquinone acaricide that acts on parasites, specifically targeting mite populations. It is utilized in agricultural formulations for effective control of these pests. Acequinocyl is suitable for various research applications, including studies in agricultural science and forensic analysis related to pest management in cannabis. -
Anti-Parasite Agent
Jietacin B is an anti-parasitic agent with demonstrated efficacy against nematodes. It effectively eliminates Burs helenchus lignicolus at a concentration of 0.25 μg/mL. This compound is a valuable tool for research applications focused on nematode resistance and parasitic control. -
Parasite
Diacetylcercosporin is a perylenequinone produced by the fungi Cercospora and Septoria, primarily targeting parasites. It demonstrates potent inhibitory activity against Plasmodium falciparum, with IC50 values of 2.75 μM for the D6 clone and 1.94 μM for the W2 strain, as well as against Leishmania donovani at an IC50 of 3.1 μM. Additionally, Diacetylcercosporin exhibits significant cytotoxic effects on various human cancer cell lines, including SK-MEL, KB, BT549, and SKOV3, with IC50 values ranging from 4.8 to 8.7 μM. This reagent also acts as a phytotoxin, inhibiting the growth of crops such as lettuce and bentgrass at a concentration of 1.62 mM. -
Parasite
Vamidothion is an organophosphorus compound that targets pests through its insecticidal and acaricidal properties. It exhibits biological activity against a range of insects and mites, facilitating the formation of phosphate adducts with tyrosine residues when degraded by human serum albumin. The resulting metabolites can be characterized using liquid chromatography quadrupole-Orbitrap mass spectrometry, making Vamidothion useful in forensic toxicology for investigating organophosphorus poisoning cases. -
Parasite
Karsil is a chemical compound utilized as an agricultural pesticide, specifically designed to target parasitic organisms. Its primary mechanism involves disrupting the biological processes of pests, leading to their mortality. Karsil is effective in controlling a variety of parasites, making it a valuable tool in agricultural research and pest management applications. -
Parasite Inhibitor
WRR-483 is an irreversible cysteine protease inhibitor targeting cruzain, demonstrating potent trypanocidal activity against Trypanosoma cruzi. This compound effectively inhibits the proliferation of the parasite in cell culture and shows significant efficacy in eradicating parasitic infection in acute Chagas disease mouse models. Its pH-dependent high affinity makes WRR-483 a promising candidate for research applications focused on combating Chagas disease. -
Antileishmanial Agent
Antileishmanial agent-28 is an effective antileishmanial compound that targets Leishmania parasites. It exhibits potent biological activity, demonstrating EC50 values of 1.5 μM against L. donovani, 13 μM against L. amazonensis, and 18 μM against J774A.1 macrophages. This reagent is applicable in research related to leishmaniasis treatment and offers insights into therapeutic strategies against this disease. -
Parasite
Spinosyn D aglycone is an active compound derived from the insecticide Spinosyn D, targeting various parasitic organisms. This compound demonstrates a reduced toxicity profile, as it is not lethal to H. virescens (tobacco budworm) neonate larvae, exhibiting an LC50 greater than 64 ppm. Its unique properties make Spinosyn D aglycone useful in studies focused on pest control and resistance mechanisms in agricultural research. -
Reverse Transcriptase Inhibitor
5'-Azido-5'-deoxythymidine is a nucleoside analogue that functions as an inhibitor of reverse transcriptase. By mimicking natural nucleosides, it integrates into viral DNA during replication, thereby terminating chain elongation and effectively inhibiting viral propagation. This compound is valuable for research into retroviral infections, including AIDS, contributing to the understanding and treatment of these diseases. -
reverse transcriptase inhibitor
Depulfavirine is a potent non-nucleoside reverse transcriptase inhibitor (NNRTI) targeting HIV-1. It demonstrates exceptional antiviral activity with an IC50 of 1.1 nM against wild-type HIV-1 and maintains effectiveness (IC50 < 100 nM) against 92% of various NNRTI-resistant clinical isolates. This compound is valuable for research into HIV resistance mechanisms and the development of novel antiviral therapies. -
AMV Reverse Transcriptase Inhibitor
Limocrocin is an inhibitor of avian myeloid leukemia virus (AMV) reverse transcriptase. This compound, derived from Streptomyces limosus, exhibits significant inhibitory activity independent of variations in template-primer concentration, substrate, or carrier protein levels. However, its efficacy diminishes with increasing concentrations of AMV reverse transcriptase. Limocrocin serves as a valuable tool for research in antiviral treatment development. -
Non-nucleoside Reverse Transcriptase Inhibitor
(R)-Efavirenz is a non-nucleoside reverse transcriptase inhibitor that acts through non-competitive inhibition of the viral enzyme. It is selectively metabolized by CYP2B6 to form 8-hydroxyefavirenz, which highlights its potential as a probe for studying the CYP2B6 active site and its catalytic mechanisms. This compound serves as a valuable tool in the research of antiviral therapeutics and the pharmacokinetics of HIV treatment. -
Reverse Transcriptase Inhibitor
Trovirdine hydrochloride is an HIV reverse transcriptase inhibitor, acting as a non-nucleoside inhibitor (NNI) of the enzyme. It demonstrates significant biological activity against HIV replication, effectively achieving inhibition at nanomolar concentrations without cytotoxic effects in infected peripheral blood mononuclear cells. This compound serves as a valuable tool for research applications focused on understanding HIV therapeutics and developing more potent derivatives for enhancing antiviral strategies. -
Reverse Transcriptase Activator
TNK-6123 is a potent reverse transcriptase activator and an analogue of Emivirine, demonstrating enhanced efficacy against drug-resistant HIV variants. Specifically, TNK-6123 exhibits improved activity against the Lys103Asn mutant of reverse transcriptase. This compound is valuable for research in HIV resistance mechanisms and may contribute to the development of effective therapeutic strategies against resistant HIV strains. -
Reverse Transcriptase Inhibitor
Mniopetal E is a potent reverse transcriptase inhibitor derived from Mniopetalum sp. 87256. This compound exhibits significant biological activity by interfering with the reverse transcription process, making it valuable for research in viral replication studies and the development of antiviral therapies. Its selective inhibition of reverse transcriptase may also provide insights into nucleic acid synthesis mechanisms in various biological systems. -
Reverse Transcriptase Inhibitor
Mniopetal B is a reverse transcriptase inhibitor derived from Mniopetalum sp. 87256. This compound demonstrates significant biological activity by interfering with the reverse transcription process, which is critical for the replication of retroviruses. Its mechanism makes Mniopetal B suitable for research applications focused on virology, HIV studies, and the development of antiviral therapies. -
Reverse Transcriptase Inhibitor
Mniopetal D is a potent reverse transcriptase inhibitor derived from Mniopetalum sp. 87256. This compound demonstrates significant biological activity by blocking the reverse transcription process, which is essential in the life cycle of retroviruses. Mniopetal D is utilized in research applications focused on antiviral drug development and understanding retroviral replication mechanisms. -
Reverse Transcriptase Inhibitor
Mniopetal F is a potent reverse transcriptase inhibitor derived from Mniopetalum sp. 87256. It effectively disrupts the replication cycle of retroviruses by hindering the reverse transcription process, making it a valuable tool in antiviral research. Mniopetal F can be utilized in studies focused on understanding viral mechanisms and developing therapeutic strategies against retroviral infections. -
Reverse Transcriptase Inhibitor
NNRT-IN-5 is a non-nucleoside reverse transcriptase inhibitor that exhibits potent antiviral activity against HIV. This compound functions by binding to the reverse transcriptase enzyme, disrupting the viral replication process. NNRT-IN-5 is primarily utilized in research to explore HIV mechanisms and develop novel therapeutic strategies targeting reverse transcriptase. -
Reverse Transcriptase Inhibitor
Mniopetal C is a reverse transcriptase inhibitor derived from Mniopetalum sp. 87256. This compound exhibits significant biological activity by disrupting the reverse transcription process, making it valuable for research in molecular biology and virology. Mniopetal C can be utilized in studies focused on retroviral infections and the development of antiretroviral therapies. -
Reverse Transcriptase Inhibitor
Mniopetal A is a potent reverse transcriptase inhibitor derived from Mniopetalum sp. 87256. This compound has demonstrated significant ability to impede the reverse transcription process, making it a valuable tool in research focused on retroviral infections and related mechanisms. Its application extends to studies investigating viral replication, cellular responses to viral entry, and therapeutic developments targeting reverse transcription pathways. -
RSV Fusion Glycoprotein Inhibitor
CGR-50 is a selective inhibitor of the respiratory syncytial virus (RSV) fusion glycoprotein, demonstrating potent activity with an EC50 of 32.6 nM against RSV A2 in HEp-2 cell lines. This compound effectively blocks RSV entry by binding to the F protein, thereby inhibiting the critical process of membrane fusion. CGR-50 is a valuable tool for research dedicated to understanding and combating RSV infections. -
RSV-F Protein Inhibitor
Sisunatovir is a potent inhibitor of the respiratory syncytial virus (RSV), targeting the RSV-F protein with IC50 values of 1.4 nM and 1.0 nM for RSV A and RSV B, respectively. It effectively inhibits RSV infection and has demonstrated the ability to reduce viral titers in the lungs of murine models. This compound is valuable for research applications focused on developing therapeutic strategies against RSV infections. -
RSV Inhibitor
Zelicapavir is an orally active inhibitor of respiratory syncytial virus (RSV) specifically targeting the viral replication process. With an effective concentration (EC50) of less than 0.4 μM, it demonstrates potent antiviral activity. This compound is applicable in research focused on understanding RSV pathogenesis and developing therapeutic strategies against RSV infections. -
RSV Inhibitor
4-Methoxycinnamaldehyde is an RSV inhibitor known for its cytoprotective activity against respiratory syncytial virus. This compound demonstrates significant efficacy in human larynx carcinoma cell lines, effectively inhibiting RSV-induced cytopathic effects with an estimated IC50 value of 0.055 μg/mL. Its properties make it a valuable tool for research into antiviral therapies and understanding RSV pathogenesis. -
RSV Inhibitor
BMS-433771 is a potent orally active inhibitor targeting respiratory syncytial virus (RSV). It demonstrates efficacy against both RSV A and B strains, with an average EC50 value of 20 nM. This compound is a valuable tool for research on respiratory tract diseases, aiding in the understanding of RSV pathology and potential therapeutic interventions. -
RSV Inhibitor
VP-14637 is a novel respiratory syncytial virus (RSV) fusion inhibitor that demonstrates potent antiviral activity with an IC50 of 1.42 ng/mL. This compound specifically targets the fusion process of RSV, making it a valuable tool for studying viral entry mechanisms and evaluating potential therapeutic strategies against RSV infections. Its high efficacy positions VP-14637 as an important reagent for researchers working on respiratory viral diseases. -
RSV Inhibitor
RSV L-protein-IN-1 is a potent inhibitor of Respiratory Syncytial Virus (RSV) that targets viral polymerase with an IC50 of 0.089 μM. It effectively disrupts RSV mRNA synthesis by inhibiting the guanylation of viral transcripts, demonstrating an EC50 of 0.021 μM. In addition to its antiviral activity, RSV L-protein-IN-1 shows moderate cytotoxicity (CC50=8.4 μM in HEp-2 cells) and has been shown to lower virus titers in mouse models of RSV infection, making it suitable for research applications aimed at understanding RSV pathogenesis and developing therapeutic strategies. -
RSV Inhibitor
JNJ 2408068 is a potent inhibitor of respiratory syncytial virus (RSV). This compound effectively suppresses the replication of RSV A and B subtypes in pulmonary tissue, demonstrating significant antiviral activity without observable toxicity in vivo. Its minimum protective dose is approximately 0.39 mg/kg, making it a valuable tool for research into RSV pathogenesis and therapeutic interventions. -
RSV Antiviral Agent
(S)-Enzaplatovir is the S-enantiomer of the antiviral agent Enzaplatovir, targeting respiratory syncytial virus (RSV). It demonstrates potent antiviral activity with an EC50 of 56 nM against RSV, making it a valuable reagent for research focused on respiratory viral infections and their therapeutic interventions. This compound is suitable for studies investigating the mechanisms of RSV replication and potential antiviral strategies. -
RSV Inhibitor
3,4-Di-O-caffeoyl quinic acid methyl ester is a dicaffeoyl derivative that acts as an inhibitor of respiratory syncytial virus (RSV). It demonstrates significant antiviral activity against RSV, with an IC50 value of 0.78 μg/mL. This compound is useful for research applications focused on RSV-related infections and exploring potential therapeutic options. -
RSV Inhibitor
RFI-641 is a selective inhibitor of the respiratory syncytial virus (RSV), exhibiting an IC50 of 50 nM. This compound disrupts the binding and fusion processes of the virus by targeting the viral fusion protein. RFI-641 serves as a valuable tool in RSV research, aiding studies on viral replication mechanisms and the development of therapeutic strategies against RSV infections. -
hRSV Inhibitor
hRSV-IN-1 is a potent inhibitor of the human respiratory syncytial virus (hRSV), acting primarily by interfering with viral replication. This compound exhibits significant antiviral activity, making it an important tool for research in hRSV pathogenesis and treatment strategies. hRSV-IN-1 is particularly valuable for studies focusing on respiratory viral infections and the development of therapeutic interventions. -
RSV Polymerase inhibitor
RSV L-protein-IN-3 is an inhibitor of respiratory syncytial virus (RSV) polymerase, displaying an IC50 value of 10.4 μM and an EC50 value of 2.1 μM against RSV. It demonstrates reduced cytotoxicity compared to the clinical agent Ribavirin, making it a suitable candidate for further research into treating RSV infections. This compound is valuable for studies focusing on antiviral mechanisms and drug development targeting RSV. -
Anti-RSV-F Antibody
Glarivibart is a humanized IgG1κ monoclonal antibody that specifically targets the fusion F protein of Respiratory syncytial virus (RSV). This antibody exhibits substantial antiviral activity, making it a valuable tool in the study of RSV infections. Glarivibart can be utilized in various research applications focused on understanding and combating RSV-related diseases. -
Anti-RSV Agent
YM 53403 is an anti-respiratory syncytial virus (RSV) agent that demonstrates potent inhibition of RSV replication, with an EC50 of 0.20 μM. It is effective against both type A and type B RSV strains, making it valuable for research on viral infections and potential therapeutic strategies against RSV. This compound can be utilized in studies focusing on the development of antiviral agents and the mechanisms of RSV pathogenesis. -
Anti-RSV Agent
RSV-IN-6 is an anti-respiratory syncytial virus (RSV) agent that targets the M2-1 protein. It exhibits effective antiviral activity with EC50 values of 4.4 μM against the RSV-A strain and 1.3 μM against the RSV-B strain. This compound is valuable for research applications focused on developing therapeutic strategies against RSV infections. -
RSV Inhibitor
RSV L-protein-IN-5 is a potent inhibitor of Respiratory syncytial virus (RSV), demonstrating an EC50 of 0.1 μM. This compound primarily targets the RSV polymerase, with an IC50 of 0.66 μM, effectively blocking mRNA synthesis by inhibiting the guanylation of viral transcripts. Despite exhibiting moderate cytotoxicity (CC50 of 10.7 μM in HEp-2 cells), RSV L-protein-IN-5 shows significant antiviral activity in preclinical mouse models of RSV infection, making it a valuable tool for RSV research and therapeutic development. -
RSV Inhibitor
RSV-IN-5 is a potent dual inhibitor targeting respiratory syncytial virus (RSV) fusion proteins, effective against both wild-type and mutant strains. This compound demonstrates significant anti-RSV activity, with an EC50 of 2.0 nM against the wild-type A2 F protein and 8.1 nM against the D486N-mutant F protein. Its efficacy makes RSV-IN-5 a valuable tool in research focused on RSV-related therapeutics and understanding viral resistance mechanisms. -
RSV Inhibitor
Genkwanol C is a biflavonoid that serves as an inhibitor of respiratory syncytial virus (RSV). It demonstrates potent antiviral activity against RSV in vitro, making it a valuable tool for research on viral infections and potential therapeutic applications. Its mechanism of action offers insights into the interaction between flavonoids and viral pathogens. -
Non-Antibacterial Macrolide Agent
Glasmacinal is a non-antibacterial macrolide agent that primarily targets inflammatory pathways. It exhibits significant anti-inflammatory activity, making it a valuable tool for researchers studying inflammation-related processes. This compound can be utilized in various biological research applications, including the exploration of immune response modulation and the development of novel therapeutic strategies. -
RSV Inhibitor
ent-11β-Hydroxyatis-16-ene-3,14-dione is a diterpenoid derived from the fresh roots of Euphorbia jolkinii, primarily targeting respiratory syncytial virus (RSV). This compound exhibits significant anti-RSV activity, making it a valuable tool for research in viral pathogenesis and therapeutic development focused on respiratory viral infections. Its role in inhibiting RSV positions it as a potential candidate for further exploration in antiviral research. -
RSV Polymerase Inhibitor
RSV L-protein-IN-4 is a noncompetitive inhibitor of the respiratory syncytial virus (RSV) polymerase, exhibiting an IC50 value of 0.88 μM. This compound demonstrates significant antiviral activity against various RSV strains, with an EC50 of 0.25 μM. RSV L-protein-IN-4 is essential for research into antiviral therapies targeting RSV infections. -
RSV Inhibitor
TP0591816 is a highly potent dual inhibitor targeting both wild-type and mutant respiratory syncytial virus (RSV) fusion proteins, exhibiting effective inhibition with EC50 values of 0.27 nM for wild-type and 0.70 nM for the D486N mutant. This compound demonstrates significant antiviral activity, making it a valuable tool for RSV research and potential therapeutic development. Researchers can utilize TP0591816 to explore mechanisms of RSV pathogenesis and evaluate antiviral strategies against this respiratory virus. -
RSV Epitope
Fusion Glycoprotein (92-106) is a peptide derived from the fusion protein of respiratory syncytial virus (RSV). It serves as a MHC class I-restricted cytotoxic T lymphocyte (CTL) epitope, with all 15 amino acids essential for optimal recognition by CTLs. This reagent is valuable for research in virology and immunology, particularly in the evaluation of T cell responses to RSV and the development of vaccines targeting RSV. -
RSV Inhibitor
BMS-433771 dihydrochloride hydrate is a selective inhibitor of respiratory syncytial virus (RSV), effectively targeting both RSV A and B strains. With an average EC50 of 20 nM, it demonstrates significant antiviral activity. This compound is valuable for research applications focused on respiratory tract diseases and the mechanisms underlying RSV infection and pathogenesis. -
RSV Polymerase Inhibitor
RSV L-protein-IN-2 is a noncompetitive inhibitor of the Respiratory Syncytial Virus (RSV) polymerase, exhibiting an IC50 value of 4.5 μM. This compound demonstrates significant antiviral activity against long strains of RSV, with an EC50 of 1.3 μM. It is applicable in research focused on developing therapeutic strategies against RSV infections and understanding viral replication mechanisms.
